Hyperparathyroidism News and Research

RSS
Hyperparathyroidism is a condition in which the parathyroid gland (one of four pea-sized organs found on the thyroid) makes too much parathyroid hormone. This causes a loss of calcium from the bones and an increased level of calcium in the blood. Symptoms include bone pain and kidney problems.

In most cases doctors don't know the cause. The vast majority of cases occur in people with no family history of the disorder. Only about 5 percent of cases can be linked to an inherited problem. Familial multiple endocrine neoplasia type 1 is a rare, inherited syndrome that affects the parathyroids as well as the pancreas and the pituitary gland. Another rare genetic disorder, familial hypocalciuric hypercalcemia, is sometimes confused with typical hyperparathyroidism. Each accounts for about 2 percent of primary hyperparathyroidism cases.

In the United States, about 100,000 people develop the disorder each year. Women outnumber men two to one, and risk increases with age. In women 60 years and older, two out of 1,000 will develop hyperparathyroidism each year.
Calcium link to PHPT shown

Calcium link to PHPT shown

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Safe vitamin D treatment without raising calcium levels

Safe vitamin D treatment without raising calcium levels

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Aldosteronism linked to poor bone health

Aldosteronism linked to poor bone health

Spectrum initiates enrollment in RenaZorb Phase 1 trial in healthy volunteers

Spectrum initiates enrollment in RenaZorb Phase 1 trial in healthy volunteers

Positive results from Cytochroma CTAP101 Phase 2b clinical trial for CKD

Positive results from Cytochroma CTAP101 Phase 2b clinical trial for CKD

Amgen enters agreement to acquire KAI Pharmaceuticals

Amgen enters agreement to acquire KAI Pharmaceuticals

One-side parathyroid surgery has poorer long-term outcomes

One-side parathyroid surgery has poorer long-term outcomes

Living-donor parathyroid gland transplant allows young woman to forgo 60 pills per day

Living-donor parathyroid gland transplant allows young woman to forgo 60 pills per day

KAI commences enrollment in KAI-4169 second Phase 2 study for CKD-MBD

KAI commences enrollment in KAI-4169 second Phase 2 study for CKD-MBD

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia

Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia

KAI enters KAI-4169 development and commercialization agreement with Ono

KAI enters KAI-4169 development and commercialization agreement with Ono

AACE's five-tiered approach to elimination of endocrine healthcare disparities

AACE's five-tiered approach to elimination of endocrine healthcare disparities

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

Cytochroma initiates CTAP101 repeat-dose safety, efficacy study in vitamin D insufficiency, SHPT and CKD

Cytochroma initiates CTAP101 repeat-dose safety, efficacy study in vitamin D insufficiency, SHPT and CKD

U.S. District Court grants injunction for Sensipar patents

U.S. District Court grants injunction for Sensipar patents

Kanis receives Hamdan Award for Medical Research Excellence in osteoporosis

Kanis receives Hamdan Award for Medical Research Excellence in osteoporosis

Indian study confirms vitamin D deficiency as risk factor for hip fracture

Indian study confirms vitamin D deficiency as risk factor for hip fracture

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.